We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $62.96 · 25 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
BioNTech and Bristol Myers Squibb Announce Promising Interim Data for Pumitamig Combined with Chemotherapy in First-Line Non-Small Cell Lung Cancer at ASCO 2026 - Quiver Quantitative
BioNTech and Bristol Myers Squibb Announce Promising Interim Data for Pumitamig Combined with Chemotherapy in First-Line Non-Small Cell Lung Cancer at ASCO 2026 Quiver Quantitative
Norges Bank Acquires Shares of 36,100,698 Bristol Myers Squibb Company $BMY - MarketBeat
Norges Bank Acquires Shares of 36,100,698 Bristol Myers Squibb Company $BMY MarketBeat
Eurizon Capital SGR S.p.A. Acquires New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Eurizon Capital SGR S.p.A. Acquires New Holdings in Bristol Myers Squibb Company $BMY MarketBeat
Fideuram Asset Management Ireland dac Takes Position in Bristol Myers Squibb Company $BMY - MarketBeat
Fideuram Asset Management Ireland dac Takes Position in Bristol Myers Squibb Company $BMY MarketBeat
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | After market close (AMC) | $1.61 | — | — | $11.72B | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $1.2 | — | — | $11.2B | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-4.45 | — | — | $35.96B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-5.05 | — | — | $24.07B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 04. 10. | B of A Securities | — | Maintain | Buy → Buy | — | B of A Securities: Buy |
| 2026. 04. 08. | Guggenheim | — | Maintain | Buy → Buy | — | Guggenheim: Buy |
| 2026. 04. 08. | Cantor Fitzgerald | — | Maintain | Neutral → Neutral | — | Cantor Fitzgerald: Neutral |
| 2026. 03. 18. | HSBC | — | Maintain | Hold → Hold | — | HSBC: Hold |
| 2026. 02. 25. | RBC Capital | — | Initiate coverage | — → Sector Perform | — | RBC Capital: Sector Perform |
| 2026. 02. 23. | Piper Sandler | — | Maintain | Overweight → Overweight | — | Piper Sandler: Overweight |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 11,535,106 | $699.6B | 0.60% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 4,662,042 | $251.47B | 0.39% | — | New position |
| 3 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 3,004,111 | $162.04B | 0.27% | — | New position |
| 4 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 531,198 | $32.22B | 0.06% | — | New position |